<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To establish incidence and risk factors for development of second malignant <z:hpo ids='HP_0002664'>neoplasms</z:hpo> after high-dose chemo/radiotherapy (HDT) and autologous hematopoietic stem cell transplantation (AHSCT), the case files of 800 consecutive patients who underwent AHSCT at our institution between June 1982 and December 2000 were reviewed </plain></SENT>
<SENT sid="1" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo>, 26 patients developed 29 second <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> (nine <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>)/<z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 16 solid <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and four <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> (LPDs)) for a 15-year cumulative incidence of 11% (95% confidence interval (CI), 5-18%) </plain></SENT>
<SENT sid="2" pm="."><plain>These second <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> occurred at a median of 68 (range 1.5-177) months following AHSCT </plain></SENT>
<SENT sid="3" pm="."><plain>The relative risk (RR) compared to the general population of developing a <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancy</z:e> following AHSCT was 3.3 (CI 2.2-4.7) P&lt;0.001 </plain></SENT>
<SENT sid="4" pm="."><plain>The RR of developing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, LPD and a <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> was 47.2 (CI 21.5-89.5) P&lt;0.001, 8.1 (2.2-20.7) P=0.002 and 1.98 (1.1-3.2) P=0.009, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>In multivariate analysis, age &gt;or=35 years at the time of AHSCT (P=0.001) and an interval from diagnosis to AHSCT &gt;or=36 months (P=0.03) were associated with a greater risk of developing a <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancy</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Patients who have undergone HDT and AHSCT are at significant risk for developing a <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancy</z:e> and should receive indefinite follow-up </plain></SENT>
</text></document>